Canaccord Genuity analyst Matt Bottomley maintained a Buy rating on Aphria (NASDAQ:APHA) on Thursday, setting a price target of C$11, which is approximately 1.52% above the present share price of $8.42.
Bottomley expects Aphria to post earnings per share (EPS) of -$0.02 for the fourth quarter of 2020.
The current consensus among 6 TipRanks analysts is for a Strong Buy rating of shares in Aphria, with an average price target of $8.16.
The analysts price targets range from a high of $12.05 to a low of $6.41.
In its latest earnings report, released on 08/31/2020, the company reported a quarterly revenue of $144.69 million and a net profit of $22.79 million. The company's market cap is $2.03 billion.
According to TipRanks.com, Canaccord Genuity analyst Matt Bottomley is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 16.6% and a 53.63% success rate.
Aphria, Inc. engages in the production and supply of medical cannabis. It operates through the following segments: Cannabis Operations, Distribution Operations, and Business Under Development. The Cannabis Operations segment produces, distributes, and sells both medical and adult-use cannabis. The Distribution Operations segment are carried out through its wholly owned subsidiaries ABP, FL Group, and CC Pharma. The Distribution Under Development segment includes operations in which the firm has not received final licensing or has not commenced commercial sales from operations. The company was founded by Cole Cacciavillani and John Cervini on June 22, 2011 and is headquartered in Leamington, Canada.